The Federal Trade Commission (FTC) issued civil subpoenas to Johnson & Johnson (J&J) in June as part of an antitrust investigation into the contracting practices for the autoimmune drug Remicade, the originator infliximab sold by its Janssen unit, the company said in a regulatory filing on Monday.
The Federal Trade Commission (FTC) issued civil subpoenas to Johnson & Johnson (J&J) in June as part of an antitrust investigation into the contracting practices for the autoimmune drug Remicade, the originator infliximab sold by its Janssen unit, the company said in a regulatory filing on Monday.
In the 10-Q filing with the Securities and Exchange Commission, J&J said that the FTC had issued a civil investigative demand (CID). The equivalent of a subpoena, a CID is one tool the FTC can use to determine whether the contracting practices were legal.
In 2017, Pfizer sued J&J, alleging that J&J’s contracts with payers for Remicade were anticompetitive and aimed to block sales of Pfizer’s infliximab biosimilar, Inflectra, which was approved in 2016.
Pfizer argues in the lawsuit that J&J’s insurer contracts provide discounts in exchange for providing a preference to Remicade. In addition, Pfizer says the contracts only pay for Inflectra if Remicade is proven to be ineffective. J&J is fighting the Pfizer lawsuit, but in August 2018, the district court for the Eastern District of Pennsylvania denied J&J’s motion to dismiss the case.
In a statement sent to The Center for Biosimilars®, Pfizer said it also received a CID in June.
“We believe the Federal Trade Commission’s (FTC’s) decision to open an investigation into the competitiveness in the biosimilars market is an important step, which we hope will lead to a robust, competitive marketplace for patients and physicians to access biosimilar medicines,” said Pfizer’s representative. “As Pfizer’s complaint alleges, J&J’s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation—price. Today, Inflectra has an Average Selling Price that is more than 22% lower than Remicade. Despite these facts, J&J has not lost substantial volume or share of sales—counter to what should occur in a competitive market.”
Remicade, an infusion, is approved for use for rheumatoid arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis. It about $4000 per dose, or $26,000 per year.
In the 10-Q filing, J&J said it “operates in an environment increasingly hostile to intellectual property rights.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.